Form 4: Vir Biotech Officer Granted Equity, Sells Shares for Tax

Vir Biotechnology's SVP, Chief Accounting Officer, Brent Sabatini, received new equity awards and sold shares to cover tax obligations.

Summary

• Brent Sabatini, SVP, Chief Accounting Officer of Vir Biotechnology, Inc. (VIR), acquired 25,000 shares of common stock in the form of Restricted Stock Units (RSUs) on February 22, 2026, under the Issuer's Equity Incentive Plan.
• On February 23, 2026, Sabatini sold 1,829 shares of common stock at a price of $7.4528 per share. This sale was automatic and mandatory under a Rule 10b5-1 arrangement to satisfy tax withholding obligations related to the vesting of RSUs, and was not a discretionary trade.
• Sabatini also acquired an option to buy 50,000 shares of common stock on February 22, 2026, with an exercise price of $7.56 per share.
• Following these transactions, Sabatini beneficially owns 71,043 shares of common stock and options for 50,000 shares.
• The stock option will vest 25% on February 22, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, and expires on February 21, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction, reflecting compensation awards and mandatory tax-related sales, which generally indicates management alignment without signaling discretionary market sentiment.

Positives

• The acquisition of 25,000 Restricted Stock Units and an option for 50,000 shares aligns the interests of the SVP, Chief Accounting Officer, with those of shareholders, incentivizing long-term performance.
• The equity grants are part of the company's compensation plan, indicating continued commitment to retaining and motivating key executives.

Negatives

• A sale of 1,829 shares, even for tax purposes, reduces the direct ownership stake of the reporting person.

Risks

• The value of the acquired equity awards (RSUs and stock options) is subject to the market performance of Vir Biotechnology's common stock.
• Future stock price volatility could impact the ultimate value realized from the stock options and RSUs.

Future Outlook

The filing details future vesting schedules for the granted stock options, with 25% vesting on February 22, 2027, and the remainder vesting in 36 equal monthly installments thereafter, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity compensation, including RSUs and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This filing reflects a routine compensation event for a senior officer at Vir Biotechnology, consistent with industry norms for executive remuneration.

Related Party Transactions

• Acquisition of 25,000 Restricted Stock Units (RSUs) by Brent Sabatini from Vir Biotechnology, Inc. under the Issuer's Equity Incentive Plan.
• Acquisition of an option to buy 50,000 shares of common stock by Brent Sabatini from Vir Biotechnology, Inc.

Stakeholder Impact

• Shareholders: The equity grants align management's financial interests with shareholder value creation, potentially fostering long-term growth.
• Employees (specifically the reporting person): The grants represent a significant component of executive compensation, incentivizing performance and retention.

Next Steps

• Continued vesting of the acquired stock options, with the first 25% vesting on February 22, 2027.
• Subsequent monthly vesting of the remaining stock options over 36 months.

Key Dates

Recommendation

The filing details routine compensation-related equity grants and a mandatory tax withholding sale by a senior officer. These transactions do not reflect discretionary market sentiment or significant new information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Compensation, Brent Sabatini, Tax Withholding